Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

American Society of Clinical Oncology (ASCO) - Tập 31 Số 9 - Trang 1157-1163 - 2013
Sara A. Hurvitz1, Luc Dirix1, Judit Kocsis1, Giulia Bianchi1, Janice Lu1, J. Vinholes1, Ellie Guardino1, Chunyan Song1, Barbara Tong1, Vivian Ng1, Yu-Waye Chu1, Edith A. Perez1
1Sara A. Hurvitz, University of California at Los Angeles Jonsson Comprehensive Cancer Center and Translational Oncology Research International, Los Angeles, CA; Luc Dirix, Sint-Augustinus Hospital, Antwerp, Belgium; Judit Kocsis, Semmelweis University Hospital, Budapest, Hungary; Giulia V. Bianchi, Fondazione Istituto Di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy; Janice Lu, State University of New York at Stony Brook, Stony Brook, NY; Jeferson Vinholes, Clinica...

Tóm tắt

Purpose Trastuzumab emtansine (T-DM1), an antibody-drug conjugate composed of the cytotoxic agent DM1 conjugated to trastuzumab via a stable thioether linker, has shown clinical activity in single-arm studies enrolling patients with human epidermal growth factor receptor 2 (HER2) –positive metastatic breast cancer (MBC) whose disease had progressed on HER2-targeted therapy in the metastatic setting. Patients and Methods Patients (N = 137) with HER2-positive MBC or recurrent locally advanced breast cancer were randomly assigned to trastuzumab plus docetaxel (HT; n = 70) or T-DM1 (n = 67) as first-line treatment until disease progression or unacceptable toxicity. Primary end points were investigator-assessed progression-free survival (PFS) and safety. Key secondary end points included overall survival (OS), objective response rate (ORR), duration of objective response, clinical benefit rate, and quality of life. Results Median PFS was 9.2 months with HT and 14.2 months with T-DM1 (hazard ratio, 0.59; 95% CI, 0.36 to 0.97); median follow-up was approximately 14 months in both arms. ORR was 58.0% (95% CI, 45.5% to 69.2%) with HT and 64.2% (95% CI, 51.8% to 74.8%) with T-DM1. T-DM1 had a favorable safety profile versus HT, with fewer grade ≥ 3 adverse events (AEs; 46.4% v 90.9%), AEs leading to treatment discontinuations (7.2% v 40.9%), and serious AEs (20.3% v 25.8%). Preliminary OS results were similar between treatment arms; median follow-up was approximately 23 months in both arms. Conclusion In this randomized phase II study, first-line treatment with T-DM1 for patients with HER2-positive MBC provided a significant improvement in PFS, with a favorable safety profile, versus HT.

Từ khóa


Tài liệu tham khảo

10.1634/theoncologist.2008-0230

10.1200/JCO.2008.19.9844

10.1126/science.3798106

10.1200/JCO.1993.11.10.1936

10.1200/JCO.2006.07.0250

10.1200/JCO.1996.14.3.737

10.1200/JCO.1999.17.9.2639

10.1200/JCO.2002.20.3.719

10.1056/NEJM200103153441101

10.1200/JCO.2005.04.173

10.3816/CBC.2005.n.047

10.1002/pon.1245

10.1158/0008-5472.CAN-08-1776

10.1007/s10549-010-1090-x

10.1016/j.canlet.2011.03.002

10.1200/JCO.2009.26.2071

10.1200/JCO.2011.40.5902

10.1200/JCO.2010.29.5865

Hurvitz SA, Presented at European Multidisciplinary Cancer Congress

Perez EA, Presented at European Society of Medical Oncology

10.1093/jnci/92.3.205

10.1200/JCO.1997.15.3.974

10.1016/j.jclinepi.2004.01.012

10.1634/theoncologist.2007-0204

Hamberg P, 2011, Clin Breast Cancer, 11, 103, 10.1016/j.clbc.2011.03.003

10.1016/j.ctrv.2011.08.001

10.1097/CAD.0b013e32834e2fe4

10.1200/JCO.2006.09.1611

10.1200/JCO.2007.11.6699

10.1007/s10549-011-1725-6

10.1002/cncr.26213

10.1185/03007991003590860

10.1056/NEJMoa1209124

Ellis PA, 2011, J Clin Oncol, 29, 7s

Thông tin
Thông tin xuất bản

American Society of Clinical Oncology (ASCO)

Tập 31 Số 9

1157-1163

Thông tin tác giả